The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.
The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.
The firm attributes the positive results to efforts to strengthen its US diagnostics business and stabilize its core diagnostics product families of H. pylori and food testing.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
The studies provide further support for Meridian's Illumigene Malaria as a tool for routine screening of travelers in non-endemic areas of the world.
The firm has launched a line of 60 rapid immunoassays aimed at emerging markets, and plans to emphasize its menu to drive uptake of its molecular platform.
What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.
A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.